This article is more than 5 years old. Information may no longer be current.

BioTime receives NIH grant for retinal restoration program

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The NIH awarded a grant of $743,345 to BioTime to advance its next-generation retinal restoration program, according to a press release.

The award, from the Small Business Innovation Research program at the NIH, is the second year of funding of a $1.6 million grant.

“This NIH grant program is incredibly competitive, so this award provides further validation of our advances in retinal restoration initiatives, in a continued effort to develop a robust pipeline of cell therapy products for ophthalmology,” Francois Binette, PhD, senior vice president and head of global development at BioTime, said in the release.

The retinal restoration program has successfully grown complete human 3-D retinal tissue derived from human pluripotent cells, the release said. The company is working toward developments to address advanced retinal diseases and injuries.